Zentalis Pharmaceuticals (NASDAQ:ZNTL) Stock Rating Upgraded by Wall Street Zen

Key Points

• Zentalis Pharmaceuticals was upgraded from a "strong sell" to a "hold" rating by Wall Street Zen, signaling a shift in analysts' outlook on the stock.
• The company's current average rating is "Hold" with a consensus price target of $8.20, while recent analyst reports have set price objectives ranging from $4.00 to $10.00.
• Zentalis Pharmaceuticals recently reported earnings per share of ($0.37), surpassing analysts' expectations of ($0.56).

Wall Street Zen upgraded shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL - Free Report) from a strong sell rating to a hold rating in a report published on Saturday morning.

A number of other brokerages have also recently weighed in on ZNTL. Wells Fargo & Company decreased their price objective on Zentalis Pharmaceuticals from $6.00 to $5.00 and set an "equal weight" rating on the stock in a report on Thursday, August 7th. Wedbush reissued a "neutral" rating and set a $4.00 price objective on shares of Zentalis Pharmaceuticals in a report on Thursday, May 15th. Finally, HC Wainwright reissued a "buy" rating and set a $10.00 price objective on shares of Zentalis Pharmaceuticals in a report on Thursday, May 15th. Four analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $8.20.

Zentalis Pharmaceuticals Stock Up 1.1%

Shares of NASDAQ ZNTL traded up $0.02 during trading hours on Friday, reaching $1.42. 459,427 shares of the stock traded hands, compared to its average volume of 1,241,273. The company has a market capitalization of $102.08 million, a P/E ratio of -0.63 and a beta of 1.71. Zentalis Pharmaceuticals has a 52-week low of $1.01 and a 52-week high of $5.44. The company's 50-day simple moving average is $1.38 and its two-hundred day simple moving average is $1.55.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The company reported ($0.37) earnings per share for the quarter, beating analysts' consensus estimates of ($0.56) by $0.19. As a group, sell-side analysts forecast that Zentalis Pharmaceuticals will post -2.42 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

Several hedge funds have recently made changes to their positions in the business. Raymond James Financial Inc. bought a new stake in shares of Zentalis Pharmaceuticals during the fourth quarter valued at approximately $68,000. Sei Investments Co. bought a new stake in Zentalis Pharmaceuticals in the fourth quarter worth $107,000. Prudential Financial Inc. bought a new stake in Zentalis Pharmaceuticals in the fourth quarter worth $39,000. JPMorgan Chase & Co. boosted its holdings in Zentalis Pharmaceuticals by 75.7% in the fourth quarter. JPMorgan Chase & Co. now owns 859,710 shares of the company's stock worth $2,605,000 after acquiring an additional 370,511 shares in the last quarter. Finally, Franklin Resources Inc. purchased a new position in shares of Zentalis Pharmaceuticals in the fourth quarter worth $323,000.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.